Savara (SVRA) said Thursday it has launched its aPAP ClearPath dried blood spot test in the US.
The test is designed to help obtain a diagnosis of aPAP, a rare autoimmune lung disease, through a finger-prick blood sample, the company said.
The DBS test has achieved 100% sensitivity and specificity in a group of individuals with aPAP autoantibody status, Savara said.
Shares were almost 2% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。